Acurox Approval Could Be Impossible Given Combination Drug Regs
Executive Summary
By determining that the niacin component of King Pharmaceuticals/Acura Pharmaceuticals' Acurox, an abuse-resistant formulation of immediate-release oxycodone, is ineffective at deterring oral abuse of the opioid product, an FDA advisory committee may have precluded the possibility of approval, given the regulations governing combination products
You may also be interested in...
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?
Analgesic drugs have reached a painful point. Unwanted side effects and abuse potential have made existing drug categories such as non-steroidal anti-inflammatories and opioids unappealing prescriptions for patients in chronic pain. But a new class of antibodies that inhibit the crucial protein nerve growth factor could spell relief for millions of chronic pain sufferers - if they can demonstrate safety and efficacy
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?
Analgesic drugs have reached a painful point. Unwanted side effects and abuse potential have made existing drug categories such as non-steroidal anti-inflammatories and opioids unappealing prescriptions for patients in chronic pain. But a new class of antibodies that inhibit the crucial protein nerve growth factor could spell relief for millions of chronic pain sufferers - if they can demonstrate safety and efficacy
Acurox Drops Niacin, But King And Acura Need New Study For Reformulation
Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.